NASDAQ
NVCR
Last Price
US $15.55
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Novocure Ltd cash flow to debt ratio of -16.91% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Novocure Ltd's free cash flow has decreased 9.32% from $-69.22M last year to $-75.68M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Novocure Ltd's debt to equity ratio is 0.71, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
Novocure Ltd's debt has decreased relative to shareholder equity from 1.90 last year to 0.71 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Novocure Ltd has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Novocure Ltd earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Novocure Ltd's profit margin has increased (-7.91%) in the last year from -27.86% to -25.66%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Novocure Ltd's short-term assets of $646.73M exceed its short-term liabilities of $223.23M
Decreasing performance - ROA.
Novocure Ltd's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Novocure Ltd's return on equity of -50.82%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Novocure Ltd's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Novocure Ltd had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Novocure Ltd has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Novocure Ltd has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Novocure Ltd's yearly earnings has increased -19.21% since last year from $-168.63M to $-136.23M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Novocure Ltd's yearly revenue has increased 8.28% since last year from $605.22M to $655.35M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -31.75% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Novocure Ltd's 3-year revenue CAGR of 6.81% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Novocure Ltd had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Novocure Ltd had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Novocure Ltd has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Novocure Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Novocure Ltd is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Novocure Ltd has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Novocure Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Novocure Ltd has a price-to-book ratio of 5.37x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Undervalued - P/S ratio.
Novocure Ltd has a price-to-sales ratio of 2.63x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-50.82%
Return on equity
ROIC: -31.75%
Valuation History
-10.7X
Price to Earnings
EV/EBITDA: -13.0X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $15.55
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.